|
|
|
|
|
|
|
Atara Biotherap (ATRA)
|
|
40.7 0.9 (2.26%)
|
04-25 16:00
|
|
Open:
|
40.1
|
Pre. Close:
|
39.8
|
|
High:
|
40.75
|
Low:
|
38.7
|
|
Volume:
|
327,615
|
Market Cap:
|
1755M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
40.78 - 40.973
|
40.973 - 41.155
|
|
Low:
|
38.216 - 38.434
|
38.434 - 38.638
|
|
Close:
|
40.332 - 40.684
|
40.684 - 41.015
|
|
|
|
Technical analysis (as of: 2018-04-25 4:24:55 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a BUY today, upgraded from lower rating. This stock seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.
|
|
Target:
|
Six months: 51.63 One year: 60.30
|
|
Support:
|
Support1: 38.45 Support2: 34.90
|
|
Resistance:
|
Resistance1:
44.20 Resistance2: 51.63
|
|
Pivot:
|
39.54
|
|
Moving Averages:
|
MA(5): 39.91  MA(20): 39.03
MA(100): 32.40 MA(250): 21.82
|
|
MACD:
|
MACD(12,26):
0.23 Signal(12,26,9): 0.09
|
|
%K %D:
|
%K(14,3): 57.17 %D(3): 53.82
|
|
RSI:
|
RSI(14): 53.18
|
|
52-Week:
|
High: 49.9
Low: 11.8 Change(%): 134.6
|
|
Average Vol(K):
|
3-Month: 79080
10-Days 40542
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.ATRA has closed below upper band by 35.6%. Bollinger Bands are 19.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-19T21:08:01-04:00
Reader Inquiry: What's The Outlook For Atara Biotherapeutics After The Recent Secondary?
2018-04-15T00:25:16-04:00
Portfolio Review: Continued Market Outperformance In Q1 2018
2018-04-13T09:17:12-04:00
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
2018-04-13T00:14:18-04:00
Rounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators
2018-04-10T08:32:38-04:00
Premarket analyst action - healthcare
2018-03-27T12:59:05-04:00
Midday Gainers / Losers (03/27/2018)
2018-03-20T12:01:06-04:00
Biotechs Approaching New Waters
2018-03-16T13:24:19-04:00
Portfolio Strategy: How To Build An Impregnable Defense For A Momentous Offense?
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
